A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background: Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. Aim: The aim of the current study was to explore the psychedelic experiences and sustained impact of ketamine in major depressive disorder. Methods: In the current study, ketamine (0.44 mg/kg) was administered to 32 volunteers with major depressive disorder in a crossover design with the active-placebo remifentanil, in a magnetic resonance imaging (MRI) environment. The 11-dimension altered states of consciousness questionnaire and individual qualitative interviews were used to capture the acute psychedelic experience. The Montgomery-Asberg Depression Rating Scale and further interviewing explored lasting effects. The second qualitative interview took place ⩾3 weeks post-ketamine. Results: Greater antidepressant response (reduction in Montgomery-Asberg Depression Rating Scale at 24 h) correlated with the 11-dimension altered states of consciousness dimensions: spirituality, experience of unity, and insight. The first qualitative interview revealed that all participants experienced perceptual changes. Additional themes emerged including loss of control and emotional and mood changes. The final interview showed evidence of a psychedelic afterglow, and changes to perspective on life, people, and problems, as well as changes to how participants felt about their depression and treatments. Conclusions: The current study provides preliminary evidence for a role of the psychedelic experience and afterglow in ketamine’s antidepressant properties. Reflexive thematic analysis provided a wealth of information on participants’ experience of the study and demonstrated the psychedelic properties of ketamine are not fully captured by commonly used questionnaires.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Using thematic analysis in psychology
Braun, V., & Clarke, V. (2006) · Qualitative Research in Psychology · doi:10.1191/1478088706qp063oa · Cited by 194,414
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Reflecting on reflexive thematic analysis
Braun, V., & Clarke, V. (2019) · Qualitative Research in Sport, Exercise and Health · doi:10.1080/2159676x.2019.1628806 · Cited by 19,677 · cited 1×
“Qualitative analysis was carried out utilizing a reflexive thematic analysis approach which has been developed to explore people’s experiences (Braun and Clarke, 2006, 2019).”
MethodOne size fits all? What counts as quality practice in (reflexive) thematic analysis?
Braun, V., & Clarke, V. (2021) · Qualitative Research in Psychology · doi:10.1080/14780887.2020.1769238 · Cited by 9,727
Kallio, H., Pietilä, A., Johnson, M., & Kangasniemi, M. (2016) · Journal of Advanced Nursing · doi:10.1111/jan.13031 · Cited by 4,295
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 4×
“Psychotomimesis describes alterations in perception and thought (e.g. paranoia and delirium) brought on by drugs such as ketamine but also phencyclidine hydrochloride (PCP) and, lysergic acid diethylamide (LSD) among others, particularly in relation to pathological psychosis (Krystal et al., 1994).”
BackgroundInfluentialGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…of the lasting changes in perspective or perception of oneself or one’s depression after taking just a single dose of these drugs, both in consideration of and beyond alleviation of the symptoms of depression (Griffiths et al., 2016; Majić et al., 2015; Roseman et al., 2018; Watts et al., 2017).”
BackgroundGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Teasdale, J. D., Segal, Z., & Williams, J. M. G. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)e0011-7 · Cited by 1,349 · cited 2×
“…information processing exists in “limited capacity channels” which suggests that once the mind is decentered, if these limited channels can then be filled with nonruminative material, then at least for a period of time, the person will experience some relief from rumination (Teasdale et al., 1995).”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“As an active placebo, remifentanil offered several advantages over other options such as midazolam (for example, as used by Murrough et al. (2013)) such as no known antidepressant/anxiolytic properties.”
BackgroundREBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 6×
“…downstream glutamatergic action and the consequences for neural plasticity provide plausible shared mechanisms by which ketamine, LSD, psilocybin, ayahuasca, MDMA, and other psychedelic drugs may exert their therapeutic effects (Ly et al., 2018; Reiff et al., 2020; Vollenweider and Kometer, 2010).”
BackgroundInfluentialPsychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 5×
“Importantly, these ASC dimensions relate to mystical experiences (Studerus et al., 2010; Majić et al., 2015) and are not captured by the commonly used CADSS or BPRS questionnaires (Luckenbaugh et al.”
BackgroundMethodInfluentialPsychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649 · cited 4×
“…downstream glutamatergic action and the consequences for neural plasticity provide plausible shared mechanisms by which ketamine, LSD, psilocybin, ayahuasca, MDMA, and other psychedelic drugs may exert their therapeutic effects (Ly et al., 2018; Reiff et al., 2020; Vollenweider and Kometer, 2010).”
BackgroundInfluentialValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589 · cited 3×
“A second area of interest has been determining the nature of the lasting changes in perspective or perception of oneself or one’s depression after taking just a single dose of these drugs, both in consideration of and beyond alleviation of the symptoms of depression (Griffiths et al., 2016; Majić et al., 2015; Roseman…”
BackgroundThe Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 2×
“…has explored mechanisms of entropy, functional, and effective connectivity and plasticity that may mediate the therapeutic benefits of psychedelic experiences (Carhart-Harris et al., 2012; 2014; Gilbert and Zarate Jr, 2020; Johnson et al., 2019; Nutt, 2019; Vollenweider and Kometer, 2010).”
BackgroundWilliams, J. B. W., & Kobak, K. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.032532 · Cited by 463 · cited 1×
“The primary outcome measure in the study was change in MADRS (Williams and Kobak, 2008) at 1 day post-infusion compared to the baseline (pre-infusion).”
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · cited 4×
“A recent meta-analysis (Mathai et al., 2020) reported that of eight included studies, only three demonstrated a relationship between the acute psychedelic effects of ketamine and the antidepressant response (Luckenbaugh et al., 2014; Phillips et al., 2019; Sos et al., 2013).”
BackgroundMethodInfluentialPredicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413 · cited 3×
“…al., 2016), Mystical Experience Questionnaire (Barrett et al., 2015; Griffiths et al., 2006), and Emotional Breakthrough Inventory to allow direct comparison with psilocybin research (Roseman et al., 2019) and to facilitate a better understanding of ketamine as a psychedelic therapy for depression.”
BackgroundInfluentialMcGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366 · cited 3×
“…with such "challenging experiences" encompassing feelings such as intense grief, fear, death, insanity, isolation, physical distress, and paranoia (Barrett et al., 2016) (note that the specificity of the term "challenging experiences" means they are not simply equivalent to the negative…”
BackgroundMethodKishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359 · cited 1×
“Ketamine has been increasingly researched as an antidepressant in the last decade (Fond et al., 2014; Kishimoto et al., 2016; McGirr et al., 2014).”
BackgroundKetamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339 · cited 1×
“Ketamine has been increasingly researched as an antidepressant in the last decade (Fond et al., 2014; Kishimoto et al., 2016; McGirr et al., 2014).”
BackgroundDo the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 5×
“…relate to mystical experiences (Studerus et al., 2010; Majić et al., 2015) and are not captured by the commonly used CADSS or BPRS questionnaires (Luckenbaugh et al., 2014; Valentine et al., 2011; Niciu et al., 2014; Sos et al., 2013; Phillips et al., 2019; Berman et al., 2000) that assess the…”
BackgroundMethodInfluentialKetamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 1×
“KAP in different forms has been implemented with some success in addiction therapy (Krupitsky and Grinenko, 1997; Krupitsky et al., 2002).”
BackgroundKetamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1587556 · Cited by 217
The efficacy of cognitive–behavioral therapy and the problem of drop‐out
Bados, A., Balaguer, G., & Saldaña, C. (2007) · Journal of Clinical Psychology · doi:10.1002/jclp.20368 · Cited by 196
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165 · cited 3×
“, 2015) and are not captured by the commonly used CADSS or BPRS questionnaires (Luckenbaugh et al., 2014; Valentine et al., 2011; Niciu et al., 2014; Sos et al., 2013; Phillips et al., 2019; Berman et al., 2000) that assess the presence of dissociation and psychotomimesis without revealing the qualities of these.”
BackgroundMethodSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
The psychedelic mystical experience in the human encounter with death
Pahnke, W. N. (1969) · Harvard Theological Review · doi:10.1017/s0017816000027577 · Cited by 147
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors
Sumner, R. L., McMillan, R., Spriggs, M. J., Campbell, D., Malpas, G., Maxwell, E., Deng, C., Hay, J., Ponton, R., Sundram, F., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.07.009 · Cited by 32 · cited 8×
“Full screening criteria, inclusion and exclusion criteria is published in Sumner et al. (2020a).”
BackgroundMethodResultInfluential
Cited by
Schimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J., Ketzitzidou-Argyri, E., Grabski, M., & Morgan, C. J. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695335 · Cited by 65
“Additionally, in a recent report antidepressant response was correlated with dimensions of altered states of consciousness such as feelings of unity, spirituality and insight (15).”
BackgroundOnofrj, M., Russo, M., Delli Pizzi, S., De Gregorio, D., Inserra, A., Gobbi, G., & Sensi, S. L. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02691-0 · Cited by 43
“VH occur in one-third of patients who underwent ketamine administration [61].”
BackgroundSuicide prevention and ketamine: insights from computational modeling
Charlton, C. E., Karvelis, P., McIntyre, R. S., & Diaconescu, A. O. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1214018 · Cited by 7
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Metadata
- Authors
- Sumner, R. L., Chacko, E., McMillan, R., Spriggs, M. J., Anderson, C., Chen, J., French, A., Jung, S., Rajan, A., Malpas, G., Hay, J., Ponton, R., Muthukumaraswamy, S. D., & Sundram, F.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-03-30
- Volume
- 35
- Issue
- 8
- Pages
- 946-961
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3140816870
- Cited by
- 72
- References
- 45
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.